This month’s Back to Basics feature is a useful wallchart showing the five key functions of the kidney which include making balancing salt and water levels, making strong bones, boosting the production of red blood cells, controlling blood pressure and excreting waste from the blood.
Chronic kidney disease (CKD) is the term used to describe long-lasting abnormal kidney function and/or structure. It is common and often exists together with other conditions like cardiovascular disease (CVD) and diabetes. CKD is an essential diagnosis because treatment can reduce the risk of CVD and prevent or slow progression to kidney failure. This is your briefing on important NICE guideline changes that will help us to better identify at-risk patients while making over-diagnosis less likely.
This article seeks to demonstrate the close relationship between cardiovascular disease and chronic kidney disease (CKD). It also highlights the importance of identifying people with CKD as a means of recognising people at high risk of both cardiovascular events and unplanned admissions.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending extension of the label for all metformin-containing products to included patients with stable moderate renal failure (chronic kidney disease stage 3).
Ischaemic or coronary heart disease is the single leading cause of death in any Western population but more critically is one of the leading causes of premature deaths (i.e. deaths < 75 years) in both men and women. There are numerous risk factors for ischaemic heart disease and understanding these and other comorbidities is critical to achieving optimal outcomes.
The European Commission has approved patiromer (Veltassa®) for the treatment of hyperkalaemia, which marks the first new drug licenced specifically for the treatment of hyperkalaemia in over 60 years.
Healthcare professionals should offer statins to millions of people with chronic kidney disease (CKD) to help to manage their increased risk of cardiovascular disease (CVD), according to new guidance from NICE.